rifinah 300 tablets
aventis pharma (pty) limited - rifampicin, isoniazid - tablets - each tablet contains rifampicin 300 mg, isoniazid 150mg
rimactazid 150/75 tablets
sandoz sa (pty) ltd - rifampicin, isoniazide - tablets - each tablet contains rifampicin 150mg, isoniazid 75mg
rimactazid paed 60/60 tablets
sandoz sa (pty) ltd - rifampicin, isoniazide - tablets - each tablet contains rifampicin 60mg, isoniazid 60mg
rimcure paed 3-fdc tablets
sandoz sa (pty) ltd - rifampicin ,isoniazid, pyrazinamide - tablets - each tablet contains: rifampicin 60mg, isoniazid 30mg, pyrazinamide 150mg
rifaren 300mg capsule,hard
remedica ltd (0000003171) aharnon str., lemesos, 3056 - rifampicin - capsule,hard - 300mg - rifampicin (0013292461) 300.000000000000mg - rifampicin
rifaren 150mg capsule,hard
remedica ltd (0000003171) aharnon str., lemesos, 3056 - rifampicin - capsule,hard - 150mg - rifampicin (0013292461) 150.000000000000mg - rifampicin
rifadin
sanofi-aventis new zealand limited - rifampicin 600mg - tablet - 600 mg - active: rifampicin 600mg excipient: acacia calcium stearate carmellose sodium carnauba wax colloidal silicon dioxide colophony erythrosine ethanol gelatin hard paraffin kaolin lactose monohydrate magnesium carbonate magnesium stearate maize starch microcrystalline cellulose povidone purified talc purified water sodium laurilsulfate sucrose titanium dioxide white beeswax - tuberculosis rifampicin is indicated in the treatment of all forms of tuberculosis, including fresh, advanced, chronic and drug resistant cases. rifampicin should be used in conjunction with at least one other antituberculosis medicine. leprosy rifampicin is indicated in the treatment of multibacillary and paucibacillary leprosy to effect a conversion of the infectious state to a non-infectious state. rifampicin should be used in conjunction with at least one other anti-leprosy drug. methicillin-resistant staphylococcal infections (mrsa) rifampicin can be used as an alternative to vancomycin in the treatment of mrsa. in such circumstances an appropriate companion antibiotic (e.g. fusidic acid) should always be employed. serious staphylococcal infections rifampicin has been used for the treatment of both life-threatening and serious staphylococcal infections. in such circumstances an appropriate companion antibiotic should be employed. brucellosis rifampicin may be used for the treatment of brucellosis. in such circumstances doxycycline should also be used. meningococcal carriers rifampicin is indicated for the treatment of asymptomatic carriers of n. meningitidis to eliminate meningococci from the nasopharynx. (rifampicin is not indicated for the treatment of meningococcal infection because of the possibility of the rapid emergence of resistant organisms). haemophilus influenzae rifampicin is indicated for the treatment of asymptomatic carriers of h influenzae and as chemoprophylaxis of exposed children of 4 years of age or younger. other infections infections caused by rifampicin-sensitive microorganisms such as staphylococci, streptococci, n gonorrhoeae, proteus sp., h. influenzae, e. coli and legionella sp. to prevent emergence of resistant organisms, rifampicin should be given with another antibacterial agent to which the organism has been shown to be susceptible.
rifampicin+isoniazid
nenurodyta - rifampicinas/izoniazidas - disperguojamosios tabletės - 75 mg/50 mg - rifampicin and isoniazid
rifampicin+isoniazid+pyrazinamide
nenurodyta - rifampicinas/izoniazidas/pirazinamidas - disperguojamosios tabletės - 75 mg/50 mg/150 mg - rifampicin, pyrazinamide and isoniazid
rifampicina
laboratÓrio quÍmico farmacÊutico do exÉrcito - rifampicina - rifampicinas